Changes in ambulatory glucose profile in people with type 1 diabetes using an automated insulin delivery system - two year follow-up retrospective analysis of real-world data

被引:1
|
作者
Mueller-Korbsch, Michael [1 ]
Kietaibl, Antonia [2 ]
Haufe, Yves [3 ]
Fasching, Peter [2 ]
机构
[1] MedVienna Arztezentrum, Sensengasse 3-1-1-3, A-1090 Vienna, Austria
[2] 5th Med Dept, Med Dept 5, Vienna, Austria
[3] Dexcom Deutschland GmbH, Mainz, Germany
来源
关键词
Automated insulin delivery; Diabetes mellitus type 1; Diabetes technology; Open-source AID;
D O I
10.1016/j.deman.2023.100150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The number of available automated insulin delivery (AID) systems is increasing in Austria and people with diabetes (PwD) replace sensor-augmented pump (SAP) therapy more and more frequently. The present study is the two years follow-up of our prior monocentric, retrospective analysis conducted between 2019 and 2021, comparing SAP and open-source AID systems in people with type 1 diabetes. This second-year analysis included 25 PwD and investigated glycemic changes based on ambulatory glucose profiles (AGP). In comparison to the first year, a worsening of mean glucose (125.4 to 135.2 mg/dl, P = 0.038), time in range ((TIR), 84.2 to 77.0%, P = 0.012), time above range ((TAR), 11.6% to 18.5%, P = 0.017) and glycemia risk index ((GRI), 24.8 to 35.0%, P = 0.026) was observed. The reduction of mean glucose and glucose variability with AID in the first year was due to a significant decrease in time in hyperglycemia with resulting higher TIR and lower GRI. In this second-year follow up, TIR and GRI showed a significant deterioration, a familiar phenomenon in diabetology. However, open-source AID systems showed continuous safety, as there was no increase in time below range (TBR) even after two years. Despite the slight deterioration in the glycemic parameters, open-source AID systems were able to demonstrate sufficient glycemic control according to international consensus guidelines while offering the characteristic benefits of a reduced burden of diabetes management. A descriptive comparison of different AID algorithms indicated an improved glycemic control with more advanced features such as basal rate modification, auto bolus function and autotuning. (c) 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:3
相关论文
共 50 条
  • [21] REAL-WORLD EVIDENCE OF AUTOMATED INSULIN DELIVERY (AID) USE IN A LARGE SAMPLE OF OLDER ADULTS WITH TYPE 1 DIABETES
    Stumpf, M.
    Brown, S.
    Fabris, C.
    Kovatchev, B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A140 - A141
  • [22] Real-world efficacy and safety of open-source automated insulin delivery for people with type 1 diabetes mellitus: Experience from mainland China
    Zhou, Yongwen
    Lei, Mengyun
    Yang, Daizhi
    Ling, Ping
    Ni, Ying
    Deng, Hongrong
    Xu, Wen
    Yang, Xubin
    Wheeler, Benjamin John
    Weng, Jianping
    Yan, Jinhua
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 218
  • [23] Real-World Life Analysis of a Continuous Glucose Monitoring and Smart Insulin Pen System in Type 1 Diabetes: A Cohort Study
    Pantanetti, Paola
    Cangelosi, Giovanni
    Morales Palomares, Sara
    Ferrara, Gaetano
    Biondini, Federico
    Mancin, Stefano
    Caggianelli, Gabriele
    Parozzi, Mauro
    Sguanci, Marco
    Petrelli, Fabio
    DIABETOLOGY, 2025, 6 (01):
  • [24] Incidence Hypertension and Fasting Blood Glucose from Real-World Data: Retrospective Cohort for 7-Years Follow-Up
    Ahn, Soon-Ki
    Lee, Ju-Mi
    Ji, Seon Mi
    Kim, Kyoung Hoon
    Park, Jong-Heon
    Hyun, Min Kyung
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (04) : 1 - 12
  • [25] Real-World Effectiveness of Patiromer among Hemodialysis (HD) Patients: 1Year Follow-Up on a Retrospective Cohort
    Zhou Meijiao
    Ruessmann, Despina
    Ficociello, Linda
    Gil, Mir Maria
    Arens, Hans-Juergen
    Anger, Michael S.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [26] GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study
    Holmager, Pernille
    Christensen, Merete Bechmann
    Norgaard, Kirsten
    Schmidt, Signe
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [27] GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study
    Holmager, Pernille
    Christensen, Merete Bechmann
    Norgaard, Kirsten
    Schmidt, Signe
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2025, 19 (02): : 286 - 291
  • [28] Advanced hybrid closed loop system use in elderly with type 1 diabetes: Effectiveness and safety in a prospective, observational, 1-year follow-up real-world study
    Pintaudi, Basilio
    Gironi, Ilaria
    Meneghini, Elena
    Conti, Matteo
    Guidoni, Chiara
    Di Vieste, Giacoma
    Grattieri, Anna
    Disoteo, Olga
    Mion, Elena
    Bertuzzi, Federico
    DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 2034 - 2037
  • [29] Real-world data from 1,988 people with type 1 diabetes on the Omnipod DASH® Insulin Management System with continuous glucose monitoring and cloud-based data management
    Keuthage, W.
    Hirsch, I. B.
    Weinstock, R. S.
    Hadjiyianni, I.
    Huyett, L. M.
    Jantz, J.
    Lowen, S.
    Chang, A.
    Vienneau, T.
    Ly, T. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 288 - 288
  • [30] FAST-ACTING INSULIN ASPART IMPROVES GLUCOSE CONTROL IN A REAL-WORLD SETTING: A 1-YEAR MULTICENTER STUDY IN PEOPLE WITH TYPE 1 DIABETES USING CONTINUOUS GLUCOSE MONITORING.
    Billion, L.
    De Block, C.
    Verbraeken, L.
    Sterckx, M.
    Vangelabbeek, K.
    De Block, N.
    Janssen, C.
    Van Dessel, K.
    Dirinck, E.
    Peiffer, F.
    Bolsens, N.
    Mathieu, C.
    Gillard, P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A23 - A23